Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cbl & Associates Properties (CBL) EBITDA (2021 - 2025)

Cbl & Associates Properties filings provide 10 years of EBITDA readings, the most recent being $50.7 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 28.61% to $50.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $155.5 million, a 9.41% increase, with the full-year FY2025 number at $136.5 million, up 4.05% from a year prior.
  • EBITDA hit $50.7 million in Q4 2025 for Cbl & Associates Properties, up from $29.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $50.7 million in Q4 2025 to a low of -$20.1 million in Q3 2021.
  • Median EBITDA over the past 5 years was $28.4 million (2023), compared with a mean of $24.3 million.
  • Biggest five-year swings in EBITDA: crashed 80.86% in 2022 and later soared 180.45% in 2023.
  • Cbl & Associates Properties' EBITDA stood at $17.8 million in 2021, then increased by 27.67% to $22.8 million in 2022, then skyrocketed by 65.96% to $37.8 million in 2023, then rose by 4.35% to $39.4 million in 2024, then grew by 28.61% to $50.7 million in 2025.
  • The last three reported values for EBITDA were $50.7 million (Q4 2025), $29.8 million (Q3 2025), and $35.5 million (Q2 2025) per Business Quant data.